Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma

To asess the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pediatric Glaucoma Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Eye Abnormalities Eye Diseases Glaucoma Glaucoma, Open-Angle Hydrophthalmos Infant, Newborn, Diseases Ocular Hypertension

Age range

Up to 12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Al-Azhar University

Cairo, Egypt

About this study

Recurrent pediatric glaucoma following Ahmed Glaucoma Valve (AGV) implantation presents a therapeutic challenge. This study evaluates the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

children under 12 years with previous AGV implantation for primary congenital glaucoma

Exclusion criteria

age >12 years, eyes with no light perception, and those with prior cyclodestructive procedures.

Treatment and study plan

AGV plate

Procedure

AGV plate using a 27-gauge needle

bevacizumab injection

Procedure

subconjunctival injection of bevacizumab

Primary outcomes

surgical success

Time frame: for 12 months

IOP ≤ 21 mmHg and ≥ 5 mmHg without medications

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

Evaluation of Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma

Acronym: MMC glaucoma

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: May 21, 2025
Registry last updated: May 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed